Kamada rejects negative lungs drug study

JERUSALEM, July 11 (BestGrowthStock) – Israeli biopharmaceutical
company Kamada (KMDA.TA: ) on Sunday said it “strongly rejected” a
study crticising expensive treatments for a genetic
lung-damaging disorder called alpha-1 antitrypsin deficiency.

Kamada has received approval from the U.S. Food and Drug
Administration to sell its intravenous AATD treatment called
Glassia for the disorder which causes chronic lung disease such
as emphysema. [ID:nLDE6610GV]

But scientists last week said the treatment should be
withdrawn since the drugs have no benefit, sending Kamada’s
shares down some 10 percent last Thursday. [ID:nLDE6650DW]
[ID:nLDE6670TE]

“The company strongly rejects the conclusion of researchers,
which ignore the information about its effectiveness in more
than 20 years of therapy in AAT,” Kamada said in a statement to
the Tel Aviv Stock Exchange.

It added that the FDA would not approve a drug that doesn’t
work.

Kamada also said the Danish study would not influence its
marketing targets and that it still planned to sell the drug in
the United States starting in the third quarter.

Kamada’s shares were down 1.5 percent at 21.18 shekels in
afternoon trading in Tel Aviv.
($1 = 3.87 shekels)
(Reporting by Steven Scheer; Editing by Hans Peters)

Kamada rejects negative lungs drug study